Delivery Order SPE2DB22D3016-SPE2DB25FATE2

Award Date 4/4/25
Potential Completion Date 4/25/25
Potential Value $23K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is a Delivery Order valued at $7,641.98 for the supply of NUBEQA 300 MG TABLET 120S. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of March 31, 2025. The contract is a Firm Fixed Price arrangement and does not have a set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,641.98 firm fixed-price delivery order is for the supply of NUBEQA 300 MG TABLET 120S, a pharmaceutical product, with a completion date of June 27, 2025. The contract is not set-aside and represents an open competition award. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania. The $7,280.00 firm fixed price delivery order is for the supply of 120 tablets of the drug NUBEQA 300 MG. The contract has an ultimate completion date of June 30, 2025 and is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of the prescription drug NUBEQA 300 MG TABLET 120S to federal government agencies. The contract, valued at $4,683.97, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical and has a completion date of December 10, 2024. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $48,458.50, is for the delivery of NUBEQA 300 MG TABLET 120S, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order, with a period of performance through December 13, 2024. Amerisourcebergen Drug Corp, a for-profit organization, is the prime contractor and...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) and has a ceiling value of $7,641.98. The contract is for the delivery of NUBEQA 300 MG TABLET 120S, a medical product, and is a firm fixed-price delivery order with no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through November 2026, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,641.98 firm fixed-price delivery order is for the supply of NUBEQA 300 MG TABLET 120S, a pharmaceutical product. The contract has an ultimate completion date of March 27, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide the drug NUBEQA 300 MG TABLET 120S. The firm-fixed-price delivery order has a ceiling value of $7,641.98 and an ultimate completion date of April 1, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999 through...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of NUBEQA 300 MG TABLET 120S, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $3,518.40, is a Delivery Order placed under an existing Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of the pharmaceutical product NUBEQA 300 MG TABLET 120S. The contract, valued at $3,518.40, was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a federal agency within the Department of Defense. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA, valued up to $999,999,999.00 through December 31, 2025....
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB25FATE2
    Delivery Order

This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of NUBEQA 300 MG TABLET 120S. The contract, valued at $22,925.94, is a Firm Fixed Price Delivery Order with an ultimate completion date of April 25, 2025. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award did not have a set-aside designation, indicating open competition.

Generated 7/4/25, 11:31 AM